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Right Ventricular Metabolism and Its
Efficiency
Clinical Aspects and Future Directions
Keiichiro Yoshinaga, Hiroshi Ohira, Ichizo Tsujino, Osamu Manabe,
Takahiro Sato, Chietsugu Katoh, Katsuhiko Kasai, Yuuki Tomiyama,
Masaharu Nishimura, and Nagara Tamaki
Abstract Background: Elevated pulmonary arterial pressure may increase right
ventricular (RV) oxidative metabolism in patients with pulmonary hypertension
(PH) and heart failure (HF). 11C- acetate positron emission tomography (PET) can
be used to measure RV oxidative metabolism noninvasively. The combination of
RV oxidative metabolism and cardiac work, as estimated by cardiac magnetic reso-
nance imaging (CMR), indicates RV efficiency and can provide new insights.
However, the clinical importance of these markers has not been fully studied.
The purpose of this study was to investigate the possible impacts of these markers
in patients with PH through 11C-acetate PET.
Methods: Ventricular function was assessed using magnetic resonance imaging
(MRI). Dynamic 11C-acetate PET was used to simultaneously measure RV and
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left ventricular (LV) oxidative metabolism (kmono). The RV myocardial work per
oxygen consumption index was calculated as follows: [RV stroke volume index
(SVI)/RV kmono]. PH patients who had additional or increased doses of PH-specific
vasodilator(s), based on the joint guidelines of the European Society of Cardiology
(ESC) and European Respiratory Society (ERS) for the diagnosis and management
of PH, were compared with five PH patients who had no treatment modification
(control group).
Results: PH patients showed higher RV kmono than did controls (P< 0.05). RV
oxidative metabolism was correlated with the mean pulmonary arterial pressure
(mPAP) (r¼ 0.44, P¼ 0.021), pulmonary vascular resistance (PVR) (R¼ 0.56,
P¼ 0.002), and brain natriuretic peptide (BNP) (R¼ 0.42, P¼ 0.029). Members
of the PH therapy group had reduced RV oxidative metabolism (P¼ 0.002) and
improved RV work/oxygen consumption index (P< 0.001).
Conclusions: RV oxidative metabolism increased as the correlation between
mPAP and PVR increased. PH-specific treatments reduced RV oxidative meta-
bolism. Therefore, RV metabolism and its efficiency can provide new pathophysio-
logical insights and will be a new therapeutic marker in patients with PH.
Keywords Metabolism • Pulmonary hypertension • Right ventricle • Tomography
15.1 Introduction
The right ventricle (RV) is the anterior cardiac chamber located just behind the
sternum. The RV receives systemic venous return and pumps it into the pulmonary
arteries [1]. Under normal conditions, the RV requires little energy to pump venous
blood to the pulmonary arteries since pulmonary circulation has a much lower
vascular resistance than does systemic circulation [2]. The RV therefore usually has
low oxygen consumption.
Until recently, most cardiology research was concerned with left ventricle
(LV) physiologies and pathologies. In fact, in the early twentieth century, some
groups hypothesized that human circulation could be maintained without RV func-
tion [3]. However, cardiovascular surgeons recognized the importance of RV func-
tion, and RV dysfunction appeared to be associated with major cardiovascular
events in heart failure (HF) [4]. In addition, development of state-of-the-art cardio-
vascular imaging modalities such as echocardiography, cardiac magnetic resonance
(CMR) imaging, and positron emission tomography (PET) have made it possible to
noninvasively evaluate the functional and physiological characteristics of RV myo-
cardium [5, 6]. Based on this background, research on the RV has progressed
intensively in recent years.
One of the major causes of RV dysfunction is pulmonary hypertension (PH). PH
is categorized into five groups as follows: Group 1, pulmonary artery hypertension
(PAH); Group 2, PH with LV disease; Group 3, PH associated with lung disease
and/or hypoxia; Group 4, PH due to chronic thrombosis and/or embolism; and
Group 5, miscellaneous [7]. Elevated pulmonary arterial pressure (PAP) and pul-
monary vascular resistance (PVR) may induce RV dysfunction in patients with PH
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[7]. However, the RV has a high capacity to adapt to pressure or volume overload
before failing in its function [8]. Before myocardial fibrosis and RV heart failure
develop, moderate to severe PH often leads to initial RV adaptation [9]. Given the
increased arterial pressure in pulmonary circulation, the RV may require a signifi-
cant power output in response to increased afterload, and this may increase the
demand for oxygen in the RV [10]. In this circumstance, the RV may require
improved mechanical efficiency in order to increase the power output. A study by
Wong et al. showed that idiopathic PH with RV dysfunction was associated with
increased RV myocardial oxygen consumption (MVO2) and reduced RV efficiency
[11], a situation possibly mirroring the case of LV energetics in heart failure [12–
14]. However, the study by Wong et al. lacked control subjects [11]. Yoshinaga
et al. evaluated the RV oxidative metabolism in patients with PH and showed that
patients with PH had increased oxidative metabolism in comparison with that of
normal individuals [15]. Increasing RV oxidative metabolism was associated with
several prognostic markers such as mean PAP (mPAP), PVR, and brain natriuretic
peptide (BNP). These findings suggest that elevated RV oxidative metabolism may
be a prognostic marker.
11C-acetate PET is a noninvasive technique for measuring regional and global
myocardial oxidative metabolism [13, 16–19], which is correlated with tricarbo-
xylic acid cycle flux and MVO2 [16]. RV myocardial oxidative metabolism can also
be measured noninvasively using 11C-acetate PET [15, 17, 20–22]. HF therapies
such as beta-blockers that reduce MVO2 are considered to improve the survival of
patients with HF [23]. LV cardiac efficiency can be estimated noninvasively [12] by
combining the mechanical work with the oxidative metabolism as measured by 11C-
acetate PET. This form of LV efficiency measurement has been applied to evaluate
several new HF treatments including beta-blockers, cardiac resynchronized ther-
apy, surgical reconstruction therapy, and obstructive sleep apnea (OSA) syndrome
treatments [13, 14, 24–26].
PH-specific vasodilators such as endothelin receptor antagonists, phospho-
diesterase-5 inhibitors, and prostacyclin decrease pulmonary arterial pressure
[7, 27]. These new vasodilators indeed improve survival in PH patients. Oikawa
et al. reported that reducing mPAP through the use of epoprostenol was associated
with reduced RV glucose metabolism observed by 18F-fluorodeoxyglucose (FDG)
PET [28]. However, it is not clear whether such a treatment favorably affects RV
myocardial oxidative metabolism.
The purpose of this study was to investigate the possible impacts of the intensified
PH-specific vasodilator therapy on myocardial energetics using 11C-acetate PET.
15.2 Materials and Methods
15.2.1 Study Subjects
Study subjects were recruited from the first department of medicine at the Hokkaido
University Hospital. The patient inclusion criteria were as follows: (1) a resting
mPAP 25 mmHg and a pulmonary capillary wedge pressure (PCWP)
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15 mmHg [7], (2) symptoms of PH in accordance with World Health Organization
(WHO) functional class II or III, (3) PH subtypes chronic thromboembolic pulmo-
nary hypertension (CTEPH) or PAH [29], and (4) stable condition (unchanged
for> 4 weeks).
Exclusion criteria were secondary PH due to LV disease, unstable condition of
patients, and permanent pacemaker implantation.
The study was approved by the Hokkaido University Graduate School of Medi-
cine Human Research Ethics Board. Written informed consent was obtained from
all patients.
15.2.2 Experimental Protocol
14 PH patients underwent right heart catheterization. Precapillary PH was diag-
nosed based on a mPAP 25 mmHg at rest and a PCWP 15 mmHg [7]. Among
the 14 PH patients, nine patients started or added the PH-specific vasodilators based
on the combined guidelines of the European Society of Cardiology (ESC) and the
European Respiratory Society (ERS), and these nine patients were categorized as
the intensified treatment group [30]. The remaining five patients did not change
their treatments and served as a control group.
Within 7 days of right heart catheterization, all patients underwent blood sam-
pling, CMR, and 11C-acetate PET at rest on the same day [15]. CMR and 11C-
acetate PET were repeated after 10.7 6.5 months for the intensified treatment
group (Fig. 15.1). Patients with PH but without OSA served as the control group
Fig. 15.1 Study design of the current study. BNP brain natriuretic peptide, CMR cardiac magnetic
resonance, RHC right heart catheterization, TX treatment
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and underwent CMR and 11C-acetate PET at rest at baseline and after
10.6 6.3 months (P¼NS).
WHO functional class evaluation and blood tests including BNP were measured
at baseline and follow-up.
15.2.3 Right Heart Catheterization
A complete hemodynamic evaluation was performed in all PH patients using the
standard technique for right heart catheterization. The hemodynamic measurements
included mean right atrial pressure, mPAP, and mean PCWP. Cardiac output was
determined through thermodilution. PVR was calculated as (mPAP – mean PCWP)
divided by cardiac output.
15.2.4 Measurements of BNP
Blood samples were obtained for fasting conditions the morning before the PET
studies. BNP data were obtained for all patients. Plasma BNP was measured using
immunoradiometric assay [31].
15.2.5 Cardiac Magnetic Resonance Imaging
CMR imaging studies were performed using a 1.5-T Achieva magnetic resonance
imaging system (Philips Medical Systems, Best, the Netherlands) equipped with
master gradients (maximum gradient amplitude 33 mT/m and maximum slew rate
100 mT/m/msec). CMR data acquisition was performed on patients in the supine
position with breath-holding in expiration. We used a five-element cardiac phased-
array coil and a vector cardiographic method for electrocardiogram (ECG)-gating
images. We performed localizing scans with breath-hold cine imaging and axial
orientation. Coronal images were used for cardiac anatomy evaluation. CMR
images spanned from bronchial bifurcation to diaphragm level thus allowing for
whole-heart analysis. We obtained 12 short-axis cine slices during a steady-state
free precession pulse sequence. The precession pulse sequence was as follows:
repetition time¼ 2.8 msec, echo time¼ 1.4 msec, flip angle¼ 60, acquisition
matrix¼ 192 256, field of view¼ 380 mm, slice thickness¼ 10 mm, inter-slice
gap¼ 0 mm, and phases/cardiac cycle¼ 20 [32].
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15.2.6 CMR Data Analysis
CMR images were analyzed using commercially available software (Extended MR
Work Space: version 2.6.3, Philips Medical Systems, Amsterdam, the Netherlands).
RV and LV volumes were measured using cine long-axis images. RV and LV
endocardial borders were semiautomatically traced. We then calculated the RV
ejection fraction (EF), LVEF, and RV volumes using this information [15]. RVEF
was measured in transverse (axial) orientation. LVEF was measured in short-axial
orientation [33]. All CMR images were analyzed by clinicians blinded to the
clinical and imaging data.
15.2.7 Positron Emission Tomography
All patients were instructed to fast overnight. PH patients who had vasodilator
treatments took their morning medications before the PET and CMR studies.
Patients were positioned with the heart centered in the field of view in a whole-
body PET scanner (ECAT HR+, Siemens/CTI Knoxville, TN) [34]. Dynamic PET
acquisition was initiated (10 10 s (s); 2 30s; 5 100 s; 3 180 s; 2 300 s)
[14] followed by intravenous administration of 20 mCi (mCi) [740 megabecquerel
(MBq)] 11C-acetate.
15.2.8 11C-Acetate PET Data Analysis
The reconstructed dynamic PET images were analyzed by applying a region of
interest over the whole LV and free wall of the RV myocardium in 3–5 mid-
ventricular transaxial planes [15, 20, 26]. A mono-exponential function was fit to
the myocardial time-activity data. The clearance rate constant (kmono) was deter-
mined as described previously [13, 14, 34]. The mono-exponential fit began at the
point when the blood pool was stable (usually 2–4 min after injection) (Fig. 15.2).
All data were analyzed by clinicians blinded to the clinical and imaging data.
15.2.9 RV Work Per MVO2 Index Calculation
The 11C-acetate clearance data were combined with the stroke work data to derive
myocardial efficiency using the LV work metabolic index (WMI) using the follow-
ing equation [13, 14, 26].
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WMI¼ SVI SBPHR/kmono; where SVI is the stroke volume index deter-
mined by CMR, SBP is systolic blood pressure, HR is heart rate, and kmono is the
mono-exponential rate constant for 11C-acetate clearance from the myocardium.
As a modified LV work metabolic index equation, the RV work per MVO2 index
was calculated as the ratio of RV SVI measured by CMR divided by RV MVO2.
The equation was as follows [35]:
RV work per MVO2index ¼ RV SVI = RV kmono  RV mass  20
15.2.10 Statistical Analysis
Continuous variables (using a logarithmic transformation on skewed distributions
as appropriate) are presented as mean and standard deviations. Categorical vari-
ables are presented as frequencies with percentages. Differences in results for the
PH group and the control group were examined for statistical significance with a
two-sample t-test for continuous variables. A P value of less than 0.05 was
considered indicative of a statistically significant difference. Statistical calculations
were carried out using SAS software version 9.2 (SAS Institute, Inc., Cary, NC).
15.3 Results
15.3.1 Patient Characteristics
A total of 14WHO functional class II or III PH patients were prospectively enrolled
in the study between December 2009 and July 2011, and all PH patients completed
the study protocol.
Fig. 15.2 Example of left and right myocardial time-activity data from a 11C-acetate PET acqui-
sition. A mono-exponential function fit to the myocardial clearance yields a clearance rate
constant; kmono represents the rate of oxidative metabolism and reflects MVO2. Blue line repre-
sents left ventricular (LV) myocardium time-activity curve. Orange line represents right ventri-
cular (RV) myocardium time-activity curve. Red line indicates blood time-activity curve
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The baseline characteristics of the participants are shown in Table 15.1. There
was no significant difference in mean age between members of the intensified PH
treatment patient group and those of the control group.
15.3.2 Right Heart Catheterization
The baseline right heart catheterization data is shown in Table 15.1. There was no
significant difference in the systolic PAP, diastolic PAP, mPAP, and PVR of the
intensified PH treatment group and those of the control group.
15.3.3 LV and RV Systolic Function
The RVEF and LVEF were similar in both the intensified PH treatment group and
the control group (Table 15.2).





P value intensified treatment
vs. control
Characteristics
Age (y) 48.4 12.9 52.8 17.5 NS
Male/female 3/6 2/3 NS
Medications
Vasodilators






60.9 19.5 53.2 8.8 0.14
Diastolic PAP
(mmHg)
24.8 6.4 19.4 8.0 0.54
Mean PAP (mmHg) 37.8 9.2 32.6 7.4 0.7
PVR (dynes
+ s1 + cm5)
564.4 246.93 514.6 149.4 0.35
Values are mean SD when appropriate
PAP pulmonary arterial pressure, PVR pulmonary vascular resistance
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15.3.4 LV and RV Oxidative Metabolism
There was no statistically significant difference between the LV oxidative meta-
bolism, kmono, of the intensified PH treatment group and that of the controls
(P¼ 0.72). There was also no statistically significant difference between the RV
oxidative metabolism, kmono, of the intensified PH treatment group and that of the
controls (P¼ 0.18) (Table 15.2). In addition, the RV SVI per RV kmono was similar
in both the intensified PH treatment group and the control group (P¼ 0.31).
15.3.5 Longer-Term Effects of Intensified PH-Specific
Therapy on RV Metabolism and Work per Oxygen
Consumption
The intensified PH therapy group tended to have reduced PVR compared with that
of the control group (20.6 41.7 vs. 3.4 33.2 %, P¼ 0.29). Intensified PH
therapy tended to reduce BNP (377.2 694.5 to 70.8 132.6 mol/mL, P¼ 0.18).
Intensified PH therapy significantly reduced RV oxidative metabolism
(0.044 0.008 to 0.039 0.007/min, P¼ 0.002) while increasing SVI
(31.4 10.1 to 39.3 9.6 mL/m2, P¼ 0.017) (Fig. 15.3). As a result, the intensified
PH-specific therapy significantly improved the RV work/oxygen consumption
index (730.8 253.6 to 1038.5 262.7 mL/min +m2, P< 0.001) (Fig. 15.4).
There was no significant change in LV kmono in this group (0.052 0.008 to
0.050 0.006/min, P¼ 0.35). The control group showed no changes in these
parameters (RV kmono: 0.041 0.006 to 0.049 0.01/min, P¼ 0.15, RV work/
oxygen consumption index: 829.1 362.9 to 721.5 241.2 mL/min +m2,
P¼ 0.69).





P value intensified treatment
vs. control
LVEF (%) 57.5 10.5 61.0 7.3 0.50
RVEF (%) 32.1 13.0 34.7 9.7 0.59
LV kmono (min
1) 0.052 0.008 0.058 0.006 0.72
RV kmono (min
1) 0.043 0.008 0.044 0.01 0.18
SVI/RV kmono
(mL/min1∙m2)
730.8 253.6 829.1 362.9 0.31
Values are mean SD when appropriate
LV left ventricular, LVEF left ventricular ejection fraction, RV right ventricular, RVEF right
ventricular ejection fraction, RVSV right ventricular stroke volume
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Fig. 15.3 Representative case of PAH patient who had intensified PH-specific vasodilator
therapy. LV kmono did not change after the intensified PH-specific vasodilator treatment. In
contrast, RV kmono was markedly reduced after the intensified PH-specific vasodilator therapy
Fig. 15.4 Effects of intensified PH-specific vasodilator therapy on RV work per oxygen con-
sumption index. Patients who had intensified PH-specific vasodilator therapy had a significantly
improved RV work per oxygen consumption index. In contrast, there was no significant difference
in RV work per oxygen consumption index in control group. PH pulmonary hypertension, RV right
ventricle, TX therapy
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15.4 Discussion
Intensified PH-specific vasodilator therapy tended to reduce PVR and BNP. The
intensive PH-specific therapy led to reduction in right ventricular oxidative meta-
bolism and a significant improvement in right ventricular work per oxygen con-
sumption index in patients with pulmonary hypertension.
15.4.1 Increased RV Oxidative Metabolism in Patients
with PH
The major determinants of myocardial metabolism are heart rate, contractility, and
wall stress [36, 37]. Oxygen demand in the RV may also increase with elevated
PAP [10].
In LV, heart failure is considered to be an energy-depleted state. Improved
survival through the use of beta-blockers and vasodilator therapy is in part associ-
ated with the energy-sparing effects of these medications [38].
RV MVO2 was originally measured through right coronary venous blood sam-
pling [10]. As noninvasive approaches, 11C-acetate and 15O-labeled tracers PET
have also been applied for RV oxidative measurements in HF and PH [15, 17, 22,
26, 39, 40]. The current data revealed increased RV oxidative metabolism in
patients with PH and reduced RV contraction. The current data agreed with findings
of our previous study and the study by Wong et al. [15, 39].
15.4.2 Study Population and Effects of PH-Specific
Vasodilator Therapy
In the current study, eight PH patients did not have PH-specific vasodilator therapy.
One patient had a PH-specific vasodilator, but the PH control did not reach the
standard control level. Therefore, these nine patients either started or added the
PH-specific vasodilator. The remaining five patients already received PH-specific
vasodilator treatments and they were stable. These five patients did not meet the
criteria to add further vasodilators to control their PH based on ESC and ERS
guidelines [30].
The intensified PH therapy group tended to have reduced mPAP. Although the
mPAP did not reach statistically significant levels, this finding may be due to the
small sample size, but it may still indicate that intensified PH-specific therapy had
beneficial effects. In fact, BNP also tended to be reduced after the therapy, a finding
that may indicate a secondary reduction in wall stress due to reduced mPAP. It may
therefore be appropriate to evaluate the therapeutic effects on RV energetics in this
study population.
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15.4.3 Effects of PH-Specific Vasodilator Therapy on RV
Oxidative Metabolism and Work per MVO2 Index
In the previous study, we evaluated RV power and RV efficiency using the
following equation: RV efficiency¼HRmPAP SV 1.33 104/RV
kmonoRV mass 20 [35]. Using this equation, WHO functional classification II
and III PH patients actually had increased RV power and RV efficiency compared
to patients in the control group [15]. The increasing power and RV efficiency may
be adaptive processes associated with increasing mPAP. In the LV, the LV effi-
ciency is estimated using the WMI. The WMI was calculated as follows:
WMI¼ SVI SBPHR/kmono [13]. LVHF treatments usually do not significantly
change the HR and SBP [14]. In contrast, PH-specific vasodilators significantly
reduce the mPAP [27]. Therefore, if the equation proposed by Sun et al. is simply
applied to RV efficiency measurements [35], RV efficiency may be reduced after
PH-specific vasodilator therapy since the reduction of mPAP would play a signifi-
cant role over the increasing SVI. The afterload of pulmonary circulation is usually
lower than that of systemic circulation [1, 41]. Therefore, the RV may have volume
efficiency rather than pressure efficiency as would apply in the case of the
LV. Therefore, we applied SVI per MVO2 index instead of Sun’s equation in the
current study.
The SVI per MVO2 index shows that the intensified PH-specific vasodilator
therapy significantly improved this parameter in comparison with that of controls.
The trend of mPAP reduction may contribute to these improvements. Therefore,
improving volume efficiency in the RV may be one of the therapeutic effects of
PH-specific vasodilators, and doing so may contribute to the improvement of
outcomes in patients with PH. This hypothesis should be tested in a larger study
population in the future.
15.4.4 Limitations
The thickness of the RV free wall is usually 4–5 mm, which is thinner than the LV
free wall. However, the current study population had thicker RV walls. When
radiotracer uptake is measured, the partial volume effect may significantly attenuate
the data. However, we analyzed the oxidative metabolism using mono-exponential
fitting. This approach measures clearance of the radiotracer from the myocardium.
Thus, the partial volume effect should be minimal.
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15.5 Conclusion
Intensified PH-specific vasodilator therapy led to a reduction in right ventricular
oxidative metabolism and a significant improvement in right ventricular work per
oxygen consumption index in patients with pulmonary hypertension. These effects
may contribute to the benefits of intensified PH-specific vasodilator therapy.
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